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A tight interplay of genetic predisposition and environmental
factors define the onset and the rate of progression of
chronic renal disease. We are seeing a rapid expansion of
information about genetic loci associated with kidney
function and complex renal disease. However, discovering
the functional links that bridge the gap from genetic risk loci
to disease phenotype is one of the main challenges ahead.
Risk loci are currently assigned to a putative context using
the functional annotation of the closest genes via a guilt-by-
proximity approach. These approaches can be extended by
strategies integrating genetic risk loci with kidney-specific,
genome-wide gene expression. Risk loci-associated
transcripts can be assigned a putative disease-specific
function using gene expression coregulation networks.
Ultimately, genotype–phenotype dependencies postulated
from these associative approaches in humans need to be
tested via genetic modification in model organisms. In this
review, we survey strategies that employ human
tissue–specific expression and the use of model organisms to
identify and validate the functional relationship between
genotype and phenotype in renal disease. Strategies to
unravel how genetic risk and environmental factors
orchestrate renal disease manifestation can be the first steps
toward a more integrated, holistic approach urgently needed
for chronic renal diseases.
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The genetic predisposition of an individual is a crucial factor
in renal disease manifestation. In rare instances, a mutation
of a single gene crucial for a specific renal function is
sufficient to lead to a defined renal disease. But, more
commonly, genetic risk and environmental factors together
define where, when, and how a renal disease develops
and progresses in a given individual. Renal disease genetics
has successfully defined the cause of many mono-
genetic diseases of the kidney. Recent advances in whole
genome analysis can now provide insight into the role
of common genetic variants found in human populations
for the risk and manifestation of common kidney diseases. To
define the contribution of these variants to a complex disease,
genome-wide association studies (GWASs) are the most
widely used tools to date.
A GWAS of a common, complex (non-Mendelian) disease
such as type 2 diabetes mellitus and accompanying
complications like diabetic nephropathy (DN) is aimed at
determining the statistical relationship between DNA variants
and an observable disease-related characteristic or trait.
Because of the earlier availability of microarray-based
genotyping platforms, the most commonly studied variants
are single-nucleotide polymorphisms (SNPs), where a single
base at a particular genomic location differs among indivi-
duals. Recent advances in sequencing technology also allow
the detection of other variants including structural differ-
ences in the genome, such as copy number variations, where
segments of DNA occur in unusual numbers of repetitions,
including deletions (zero repetitions), and one or more
duplications of one segment. An advantage of GWAS over
previous genetic approaches such as linkage is that asso-
ciated variants may be causal, leading via genetics to the
pathophysiology of disease. For instance, a nucleotide change
in a coding region can result in a different amino acid
when RNA is translated to protein (a non-synonymous SNP),
leading to a dysfunctional protein, and the associated
pathophysiological consequences. Other causal variants may
directly target gene regulation by changing transcription
factor–binding sites to either allow or disrupt initiation of
gene transcription. But, often, phenotype-associated variants
are only markers of an inherited genetic region containing
the causal variant.
With all the promise of the GWAS approach, the primary
challenge to explain a common, complex disease phenotype
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using a genetic study of disease-variant associations is that
discovered variants frequently have a small effect size. That is,
each associated variant individually makes a limited con-
tribution to the phenotypic outcome. This observation
suggests two plausible scenarios, both of which implicate
complex physiological interactions as the mechanism for
manifesting genetic alterations as phenotype in common
disease. The first scenario is that a common disease is due to
groups of rare variants each found in a small population of
subjects, and hence cannot be detected by comparing the
genotype of many individuals in a case–control genome-wide
association study.1 In the second scenario, multiple common
variants act in concert in an individual to lead to the disease
phenotype. In both scenarios, individual or small groups
of causative variants have independent effects on different
parts of the same cellular or tissue physiology (Figure 1). The
difference being that rare variants would each have large
physiological effect but in different small groups of affected
individuals, whereas common variants would individually
have smaller effect with a cumulative large physiological
effect apparent across the affected population. Following the
lead of systems biology, we refer to this commonly affected
physiology as a system influenced by genetic variants.
The systems hypothesis states that variants affect different
parts of the same cellular and tissue physiology to yield
a common phenotypic effect. Here we review work toward
this goal that focuses on gene regulation relative to genetic
effects in renal disease. We focus on hypothesis-generation
approaches that integrate kidney tissue–specific gene expres-
sion with genotype or GWAS results, although systems
approaches can be applied in a situation where the disease
mechanism is extrarenal. We also take a prospective look
at both near- and longer-term efforts in systems genetics
using alternative approaches and technologies involving
broader molecular and clinical measures.
Systematic studies of the genetic factors in renal disease
were initiated over two decades ago,2 and subsequently more
than 15 GWASs have been performed on various forms of
renal disease.3–19 Even with substantial numbers of patients,
GWASs only have power to detect associations of common
variants with moderate contribution (effect size) to the
phenotypes of common diseases. However, studies of rare
renal diseases can yield significant effect sizes with relatively
small populations.12,20 In these studies, subjects are geno-
typed with microarray technology designed to detect alleles
of a large set of common SNPs. Each genotyped SNP is
selected to tag, or represent, a class of SNPs within a genomic
region that are in linkage disequilibrium, which is allele
correlation due to population-specific history of recombina-
tion. This selection of SNPs is intended to allow a GWAS to
determine disease associations with these classes of SNPs,
called haplotype blocks, representing the genetic profile
of each subject. As a future alternative, high-throughput
whole genome sequencing allows genotyping of all SNPs in
an individual.21
To link genetic risk represented by the tagging SNPs
with disease, most of these studies take a case–control
strategy,6,9,11 whereas others take a quantitative trait locus
(QTL) strategy.3,6 A case–control study computes a statistical
association for each genotyped SNP between the alleles of the
SNP and case–control status for each subject. A QTL analysis
computes an association between the SNP alleles and the
value of a quantitative trait for each subject in the study.
For example, glomerular filtration rate (GFR), used as a
continuous variable, can be employed as a quantitative trait.
It also can be used for case versus control categorization—for
example, defining cases as subjects with GFR o60ml/min
per 1.73m2, and all others as controls. With both approaches,
the studies result in variants that are implicated as causal for
the phenotype examined, but do not help explain how the
genetic region represented by these variants affect cellular or
tissue physiology—another rationale for taking a systems
approach.
The systems perspective on renal disease also has a history
that has recently been reviewed by He et al22 in this
journal. In particular, gene expression studies based on renal
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Figure 1 | Illustration of the physiological effects of genetic
variants based on molecular systems commonly studied in
systems biology. Groups of variants (a) directly affect regulatory
(b) and proteomic (signaling) (c) machinery of the cell, leading to
disruption in a metabolic pathway (d) that ultimately leads to a
clinical trait (e) and the renal disease phenotype (f). Shown is a
group of regulatory and nonsynonymous single-nucleotide
polymorphisms (SNPs) and their effect: SNP A lies in the promoter
region of a gene, modifying the binding characteristics of a
transcription factor; similarly, B modifies an enhancer or repressor
for another gene, and C and D are nonsynonymous, with C having
an indirect regulatory effect because of its role as a transcription
factor. The layers illustrate that different groups of variants
may affect different parts of cellular physiology, but ultimately
impact the same phenotype. ACR, albumin–creatinine ratio;
GFR, glomerular filtration rate.
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biopsies have made an important contribution to under-
standing the role of transcriptional regulation in renal
disease. Our goal is to review ways that gene expression
can be integrated with genetic analysis to better understand
the systems effects of genetic variants leading to renal disease
phenotypes.
APPROACHES
With the exception of variants like nonsynonymous SNPs or
copy number variations that result in modified gene products
or deleted genes in affected individuals, it is frequently
difficult to establish how a phenotype-associated variant
determines the phenotypic outcome. How can we fill the gap
in the genotype–phenotype projection? A promising strategy
is to determine the molecules serving intermediary functions
between genotype and phenotype (that is, RNAs, proteins,
and metabolites) on a genomic scale (Figure 1). The use of
gene expression in the analysis of genetic variants offers two
basic techniques that help us start making the functional
genotype–phenotype link. Integrating genetic risk with gene
expression can establish associations of variants to gene
regulation, and defining a putative functional context for the
effect(s) of a variant. In human subjects, these approaches
can only identify statistical relationships, whereas studies in
model systems can allow experimentation with systemic
perturbations that help validate hypotheses derived from the
human studies. In the following, we discuss studies, some
prospective, that address each of these aspects. We focus on
variants that impact intrarenal gene regulation and the
systems context of variants that affect the regulation of genes,
but will not consider nonsynonymous or structural variants
leading to direct alterations of amino-acid sequence or a
deletion of a protein.
ASSOCIATING VARIANTS TO GENE EXPRESSION
The key to the success of using gene expression to understand
the effects of genetic variants is to relate variants to the genes
that they might affect. The traditional approach in GWAS
analysis has been to use guilt-by-proximity, in which
candidate genes are identified with a variant simply by being
nearby. In some cases, for instance, the type 1 DN candidate
(FERM domain containing 3 (FRMD3)),11 a proximal SNP
can be verified to fall within a promoter region (see next
section), but for most variants this will not be the case.
Although more complete genotyping from sequencing is
more likely to include causal variants, proximity also misses
variants that may affect enhancers or suppressors that are
known to be up to several thousand base pairs from the
regulated gene, depending on the three-dimensional struc-
ture of the DNA.23 In most GWAS studies, including the
Genetics of Kidney in Diabetes (GoKinD)11 and CKDGen
Consortium6 studies for which we discuss functional analysis
below, renal gene expression is not available from the
genotyped subjects, and guilt-by-proximity is a reasonable
rule of thumb. When expression and genotype are both
available from individuals in a study population, it is possible
to perform an expression as a QTL (eQTL) analysis to identify
associations between variants and expression of genes.
An eQTL study determines the statistical association of
genotype with transcript expression as a phenotypic trait,24,25
and can involve analysis of small groups of variants, but it is
usually an all-against-all analysis (all measured transcripts
against all genotyped variants). Although this analysis does
not yield a causal relationship, it does give a direct, rather
than inferred, relationship between SNP and the expression
of a gene. Wheeler et al.26 employed eQTLs in a restricted
way in their study of kidney function as a proxy phenotype
for aging, but no human genome-wide kidney eQTL study
has been published to date. Such studies will provide the
opportunity to link GWAS candidates directly to genes in
an unbiased, genome-wide manner, but matching a GWAS
SNP to an eQTL can still be a subtle art.27,28
An association of a SNP with a transcript encoded by a
nearby gene is defined as a cis-eQTL, and an associated
variant association far from the gene, either on the same or
a different chromosome, is called a trans-eQTL. Whereas a
cis-eQTL SNP likely tags a causal SNP that changes transcript
abundance of a nearby gene in an allele-specific manner, a
trans-eQTL has less obvious involvements in transcriptional
regulation.29 However, a trans-eQTL could identify distant
enhancers or repressors that will not be captured by tight
definitions of cis-regions (Figure 1). A model developed
by Veyrieras et al.30 suggests that putatively causative cis-
associated SNPs are concentrated near transcription start
and end sites; ranging B100 kb upstream of the start site
to no more than 40 kb downstream of the end site.
Focusing only on cis-eQTLs emphasizes variants with
direct regulatory effect, but may miss variants that have
relevant, but indirect, effect on gene regulation. Studies in
model organisms find that variants with trans (that is,
distant) effects often form hot spots. A trans–hot spot is a
variant together with a set of genes whose expression is
associated with the variant, and is identified by simply
counting nominally significant associations per variant.
Permutation testing31 is used to test the distribution of hot
spot sizes and determine empirical significance of each
observed hot spot. Such sets potentially indicate the effect
of master regulators impacting a cascade of transcripts,
particularly appealing for a systems analysis of renal disease.
Hot spots also provide an opportunity for causal analysis,
such as inferring regulatory relationships from gene coex-
pression networks.32–35 Still, there is some question as to
whether trans-effects are real or simply statistical artifacts.
Listgarten et al.,36 for instance, define and compare several
statistical models for eQTL analysis, and find that trans-
effects only occur in the weakest, suggesting that caution is
required in analyses based on trans-effects.
Clinical measures may be used in conjunction with eQTL
analysis to further refine GWAS variants. Figure 2 depicts an
approach, in which a clinical QTL analysis is performed for
the biopsy population, and the QTL SNPs are used to focus
the eQTLs on clinically relevant traits before interpreting the
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GWAS candidates. This is similar, in principle, to the
approach taken by Zhong et al.37 to identify liver and
adipose tissue eQTLs putatively involved in type 2 diabetes
mellitus. Cohorts with extensive clinical observations are
a prerequisite to these analyses. Parameters that may be
integrated with renal eQTLs include longitudinal measure-
ments of proteinuria and GFR as well as detailed histological
scoring of renal biopsies and ultrastructural morphometry.
Plasma and urine proteomic and metabolomic measurements
can provide additional opportunities for analysis, especially
in diseases where renal damage has extrarenal origins and
kidney gene expression may not be informative.
IDENTIFYING FUNCTIONAL CONTEXT
The systems hypothesis implies that each causative variant
has an effect on a cellular system that defines its functional
context in a tissue-specific manner. Most work so far has
focused on analysis of single variants, with a broader systems
strategy still in the future. In this section we present efforts to
perform analysis of the functional context of single variants
implicated in renal disease.
The identification of such a functional context is aided by
having tissue-specific gene expression. Correlations between
transcripts can be used to define a coregulation network of
renal disease in which the strongest correlations indicate
potential subsystems. By linking candidate genetic variants to
transcripts in these subsystems, followed by pathway analysis
of coregulated transcripts, it is possible to identify the
putative functional and regulatory contexts of disease-
associated genetic variants.
An example of this approach is a current project to study
GWAS candidates from the CKDGen consortium using GFR-
correlated gene expression from the European Renal cDNA
Bank (ERCB). The CKDGen study is a meta-analysis of 20
GWASs that include an aggregate of over 65,000 subjects of
European descent with chronic kidney disease (CKD) or
reduced kidney function measured by various methods of
GFR estimation.6,38 ERCB39–42 is a collection of subjects with
glomerular diseases or transplants who underwent renal
biopsies. The integration strategy employed (Figure 3) is to
use the GFR trait to link the ERCB gene expression to the
CKDGen phenotype to identify genes whose expression
correlates with GFR.
This analysis was based on candidate genes identified,
guilt-by-proximity, within 60 kb of the 16 CKD-associated
candidate SNPs from the CKDGen study. Glomerular and
tubulointerstitial gene expression was used from ERCB renal
biopsies of subjects diagnosed with a glomerular disease and
biopsies from living donor kidneys. The expression values
for the genes in proximity to the candidate were correlated
with the GFR levels for the ERCB subjects. A statistically
significant set of genes show GFR-correlated expression in the
tubulointerstitial compartment, with fewer such genes from
the glomerular compartment—most of which are correlated
in both. The majority of the correlations imply decreased
expression with loss of kidney function as measured by
lower GFR.
One of the genes with GFR-correlated expression in
both compartments is vascular endothelial growth factor A
(VEGFA), which has been implicated in progressive DN.43
Performing a pathway analysis of this gene with its GFR
coregulated genes in the ERCB gene expression data set finds
strong enrichment for the hypoxia signaling pathway.
Support for hypoxia signaling in CKD is further provided
by a promoter analysis of the hypoxia pathway transcripts
correlated with GFR defining putative common upstream
transcriptional regulators. Although this analysis is still
underway, these results provide evidence for a regulatory
and functional link between hypoxia and fibrosis in CKD, as
well as many other connections among the implicated
pathways.
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Figure 3 |Use of clinical trait–correlated tissue-specific
expression to identify genome-wide association study (GWAS)
candidate genes and coregulated genes relevant to a clinical
condition. SNP, single-nucleotide polymorphism.
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Figure 2 |Use of expression and clinical traits to compute
quantitative trait loci (QTLs) in order to identify genome-wide
association study (GWAS) candidates with putative regulatory
effect impacting clinical traits associated with the GWAS
phenotype. Kidney-specific expression QTLs (eQTLs) allow focus
on tissue-specific regulatory effects, whereas clinical QTLs narrow
further to those showing associations with measures of renal
disease progression. SNP, single-nucleotide polymorphism.
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As seen in the CKD analysis, the use of tissue-specific
expression is important to the functional analysis of
candidate genes. This is especially true in the analysis
of genes near a single candidate SNP, which have few if
any functional annotations. An example of this analytical
approach is the functional analysis of a candidate SNP
(rs1888747) from the GoKinD GWAS of type 1 DN.11 This
SNP is located in the extended promoter region of a poorly
annotated gene, FRMD3, presenting a difficult analytic
scenario involving a noncoding SNP in proximity to an
unknown gene. In this situation, genes showing correlated
expression with the candidate gene can be used to assign
a function using statistical enrichment tests. Genes sharing
function and regulation justify a systematic analysis of the
mechanism responsible for transcriptional coregulation via
promoter modeling approaches.44
Using FRMD3 as a case study, a gene coregulation network
was constructed from gene expression of early diabetic
glomerulopathy. Within this network, several hundred
transcripts were found to have correlated expression with
FRMD3. Pathway analysis identified, among others, the bone
morphogenic protein (BMP) pathway as being significantly
enriched for this set of correlated transcripts. BMP has
been reported to have a protective role in renal fibrosis
and DN.45 Analysis of the SNP-altered promoter region
together with DN coregulated BMP pathway members found
a shared regulatory transcriptional module suggestive of
common regulation of FRMD3 and BMP pathway genes in
the presence of the risk allele. These results allow the
formulation of a testable hypothesis for the role of FRMD3,
which is that the polymorphism impacts the BMP pathway as
part of the pathophysiologic cascade driving progression
in DN.
The CKD and type 1 DN examples stress the utility of
kidney tissue–specific expression data sets as a resource to
developing hypotheses for causal pathways underlying the
GWAS association between a variant and phenotype. Several
large-scale studies underway aim not only to include
comprehensive clinical measures, but also to capture renal
tissue, DNA, and other biosamples for large-scale molecular
analysis (ERCB, Systems Biology towards Novel Chronic
Kidney Disease Diagnosis and Treatment (SYSKID),46
Nephrotic Syndrome Study Network (NEPTUNE), and
others47). The availability of such measures increases the
opportunity for linking expression to GWAS phenotype-
relevant traits to focus candidate gene sets as in the CKD
study.
The CKD study illustrates the utility of GFR as a linking
trait, but other measures such as albumin–creatinine ratio,
renal histologic morphometry, and levels of metabolites in
urine may also be useful linking traits. In particular,
preliminary analysis of expression-correlated morphometric
scores suggests that they are good candidates as more
direct, and very early, measures of disease progression.48
In a clinical setting, this is especially intriguing as the
compensatory abilities of the kidney often prevent the early
detection of renal impairment by standard serum- or urine-
based parameters.
ANIMAL MODELS: FUNCTIONAL VALIDATION
The previous sections demonstrate uses of whole genome
expression data to identify or characterize novel gene variants
associated with renal disease. However, the path to clinical
utility requires experiments that demonstrate the associated
variants affect disease pathogenesis as well as define their
function. Such studies are difficult in humans and require the
use of model organisms, which can also be coupled with
in vitro systems, to validate the genetic discovery, define its
mechanism(s), and help select new therapeutic, diagnostic, or
prognostic targets. We will describe several studies, which use
model organisms in novel designs, to decode the processes by
which human genetic variants regulate their associated
diseases. Although the phenotypes in these studies are not
renal, the approaches can be applied to kidney diseases.
Mice continue to be the workhorse model organ system,
and gene function is often revealed in mice when novel genes,
identified by genotype–phenotype mapping strategies, are
deleted. Yet, generic loss- and gain-of-function approaches
will not clarify mechanisms by which associated genetic
variants regulate disease pathogenesis. However, mice can be
used to recapitulate the human phenotype caused by a
specific genetic variant and creative experimental design will
decode pathogenesis.49 The dissection of the etiology of the
hypotonia in intermediate DEND syndrome (iDEND)
provides an elegant illustration of this approach.50 iDEND
is a rare genetic disorder characterized by neonatal diabetes,
muscle hypotonia, and delayed speech and motor milestones.
Gain of-function mutations in KCNJ11 (potassium inwardly-
rectifying channel, subfamily J, member 11) are associated
with iDEND. KCNJ11 encodes the Kir6.2 inward-rectifier
type potassium channel pore and interacts with a regu-
latory sulfonylurea receptor subunit to generate a functional
adenosine triphosphate (ATP)–gated Kþ [KATP] channel.
iDEND patients are often unable to walk because of lower
extremity weakness, a phenotype that could be explain by
KATP channel expression in either the brain or skeletal
muscle. To address this question, mice were engineered to
selectively express the most common human mutation
associated with iDEND in muscle and nerve. Surprisingly,
the resulting motor phenotypes, which mimic the human
disease, show that the neuron-targeted mutation is respon-
sible for motor impairment. The clinical implications of these
data are immediate and testable. Infants with neonatal
diabetes and developmental delay, muscle weakness, and
speech problems may be more effectively treated with
sulfonylurea drugs that target the SUR1 sulfonylurea receptor
subtype, the predominant SUR regulatory subunit in the
nervous system. In addition, sulfonylurea drugs with better
blood–brain barrier penetration might increase efficacy in
children with this syndrome. Although this example focuses
on a Mendelian disorder, similar designs have been used in
mice for variants controlling common traits.51
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In contrast to mice, simple model organisms provide
opportunities for higher-throughput gene manipulation and
phenotype quantification, especially for common diseases
that often associate with many noncoding genetic variants in
genome-wide association studies. Zebrafish have been
cleverly used to dissect function of three linkage disequili-
brium blocks, which harbor noncoding SNPs reproducibly
associated with type 2 diabetes.52 The experimental design
employs a computational analysis to identify regions of
synteny between teleost and human genomes, termed
genomic regulatory blocks, that control gene expression.53,54
Highly conserved noncoding element regions, contained
within both the genomic regulatory block and diabetes risk
allele-containing linkage disequilibrium block, were used to
construct zebrafish reporter vectors. The results suggest that
diabetes mellitus–associated SNPs regulate genes that control
pancreatic development and insulin secretion. In two cases,
the highly conserved noncoding element drove expression of
the gene distant from the gene nominally associated with the
diabetes risk SNP but within the genomic regulatory block.
Additionally, this study shows that zebrafish embryos can
respond to human highly conserved noncoding element
(even if not highly conserved in teleosts) in a time- and
tissue-restricted manner. A conceptually similar design in
mice further demonstrates the utility of exploring human
gene variants associated with common diseases.55 Targeted
deletion of a 70 kb noncoding interval in mice, which is
orthologous to the 9p21 risk interval for coronary artery
disease, provided direct evidence that this region affects
coronary artery disease progression by regulating vascular cell
proliferation. As noted, these are not renal studies, but may
serve as exemplars for future kidney disease research where
the rat may be a good choice, both for modeling human
physiology and the opportunity for gene targeting (see, for
example, Sato et al.56).
DISCUSSION
Our capability to define the genetic landscape of patients
with kidney disease has reached a level of resolution
unimaginable just a few years ago, and is expected to reach
true genome-wide sequencing capabilities in the near future.
The main challenge ahead for the renal research community
is the integration of this information with renal function,
disease pathogenesis, and disease course. For progress to be
made in understanding common genetic kidney disease,
genetic variants need to be linked with phenotypic outcomes
using integrative strategies to identify intermediate cellular
and tissue disease mechanisms, and validate these mechan-
isms in model organisms. Systems effects of variants are
expected to be observable at various levels of cellular activity,
leading to a systems genetics approach where the effects of
genetic variants are identified at different levels of cellular
activity.57 By integrating metabolic and proteomic observa-
tions, in addition to measuring gene expression and clinical
traits, we can hope to better refine the effect of variants on
renal disease (Figure 4). Experience gained with systems
genetics studies already done in human,58,59 plant,60,61 and
other model systems62,63 can help guide this work forward,
providing both potential strategies and tools, as well as
cautions regarding when to expect complex environmental
and other confounders.
A key challenge for moving ahead is the ascertainment of
sufficiently large human disease cohorts with complete,
robust molecular measures and clinical observations. Having
sufficient starting material from renal tissue compartments
and urinary biosamples for metabolic or proteomic observa-
tions may pose a particular challenge to straightforward
systems genetics strategies, and hence further technical
adaptation of these approaches may be necessary. However,
the adoption of uniform protocols for procuring the samples
and data across studies will provide opportunity for more
robust analyses, and will be central to developing large
cohorts to capture genetic heterogeneity adequately. Still,
we must acknowledge that these approaches are limited
by gene expression from biopsies representing a snapshot
of regulatory activity in the kidney, and will need to look
to information capable of capturing dynamic aspects of the
disease (that is, urine-based measures) as well as epigenetic
profiles that capture the effects of prior events.
Results from the analyses of genetic candidates in humans
will be associative and require functional validation. Employ-
ing an appropriate animal model to demonstrate the systems
effect of a variant on disease pathophysiology is necessary
to confirm the hypotheses of functional interdependence
generated in silico. Ingenious use of murine transgenic
technology and human systems genetics can uncover novel
disease mechanism. Evaluating the consequences of disease
variants on regulatory pathways in the transgenic animals
will allow a feedback loop to test and refine the initial systems
genetics hypotheses.
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Figure 4 | Systems genetics strategy for studying systems
effects of candidate variants. Various high-throughput
technologies allow observation of the state of the molecular
mechanism of the cell as quantitative measures of macromolecules
(shown are RNA, proteins, and metabolites) that can be used in
quantitative trait locus (QTL) analysis.
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Understanding the genotype–phenotype continuum of
renal disease is already redefining our concepts of human
disease pathophysiology. The discovery that a single locus on
chromosome 22 can be responsible for a significant part of
the excess risk for renal disease in African Americans is a first
indication of the power of these approaches.9,20,64 Establish-
ing patient cohorts, experimental tools, and analytical
workflows will be required to integrate this information into
our current knowledge base so that we can reap many more
unexpected insights into renal disease in the near future.
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